Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002433 · ClinicalTrials.gov registry record · NA
The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
A NA study, sponsored by Amgen.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00002433 is a NA study that has completed, run by Amgen. The registered enrollment target is 12 participants.
The verdict
NCT00002433, a NA study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.
Interventions
- DRUG Interferon gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002433
The ClinicalTrials.gov registry entry for NCT00002433 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon gamma-1b is the first listed.
NCT00002433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002433 about?
NCT00002433 is a clinical study titled "The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS". To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alve...
What is the current status of trial NCT00002433?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants.
What interventions are being tested in trial NCT00002433?
The interventions under investigation include: Interferon gamma-1b (DRUG).
Who is sponsoring clinical trial NCT00002433?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.